Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Boeve

Showing results (931-940 of 957) with videos related to

Pageof 96
Sort By:
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 6, 2019
Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degenerationAdam M Staffaroni, Yann Cobigo, Sheng-Yang M Goh, et al.
Neurology|April 8, 2021
Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar DegenerationJulio C Rojas, Ping Wang, Adam M Staffaroni, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 9, 2020
Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH-EXAMINER as a potential clinical trial endpointAdam M Staffaroni, Lynn Bajorek, Kaitlin B Casaletto, et al.
Alzheimer'S Research & Therapy|March 28, 2024
A systematic review of progranulin concentrations in biofluids in over 7,000 people-assessing the pathogenicity of GRN mutations and other influencing factorsImogen J Swift, Rosa Rademakers, NiCole Finch, et al.
Nature Medicine|September 22, 2022
Temporal order of clinical and biomarker changes in familial frontotemporal dementiaAdam M Staffaroni, Melanie Quintana, Barbara Wendelberger, et al.
The Lancet. Neurology|December 8, 2019
Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort studyKatrina M Moore, Jennifer Nicholas, Murray Grossman, et al.
Acta Neuropathologica|May 28, 2019
A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevitySven J van der Lee, Olivia J Conway, Iris Jansen, et al.
Acta Neuropathologica|February 11, 2019
Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLDCyril Pottier, Yingxue Ren, Ralph B Perkerson, et al.
Acta Neuropathologica|January 20, 2020
Correction to: A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevitySven J van der Lee, Olivia J Conway, Iris Jansen, et al.
Nature Genetics|February 16, 2010
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusionsVivianna M Van Deerlin, Patrick M A Sleiman, Maria Martinez-Lage, et al.
Pageof 96

Showing results (931-940 of 957) with videos related to

Sort By:
Pageof 96
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 6, 2019
Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degenerationAdam M Staffaroni, Yann Cobigo, Sheng-Yang M Goh, et al.
Neurology|April 8, 2021
Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar DegenerationJulio C Rojas, Ping Wang, Adam M Staffaroni, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 9, 2020
Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH-EXAMINER as a potential clinical trial endpointAdam M Staffaroni, Lynn Bajorek, Kaitlin B Casaletto, et al.
Alzheimer'S Research & Therapy|March 28, 2024
A systematic review of progranulin concentrations in biofluids in over 7,000 people-assessing the pathogenicity of GRN mutations and other influencing factorsImogen J Swift, Rosa Rademakers, NiCole Finch, et al.
Nature Medicine|September 22, 2022
Temporal order of clinical and biomarker changes in familial frontotemporal dementiaAdam M Staffaroni, Melanie Quintana, Barbara Wendelberger, et al.
The Lancet. Neurology|December 8, 2019
Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort studyKatrina M Moore, Jennifer Nicholas, Murray Grossman, et al.
Acta Neuropathologica|May 28, 2019
A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevitySven J van der Lee, Olivia J Conway, Iris Jansen, et al.
Acta Neuropathologica|February 11, 2019
Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLDCyril Pottier, Yingxue Ren, Ralph B Perkerson, et al.
Acta Neuropathologica|January 20, 2020
Correction to: A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevitySven J van der Lee, Olivia J Conway, Iris Jansen, et al.
Nature Genetics|February 16, 2010
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusionsVivianna M Van Deerlin, Patrick M A Sleiman, Maria Martinez-Lage, et al.
Pageof 96